C07K 14/71
For growth factors
Official title: for growth factors; for growth regulators
C07K14/71 (For growth factors) appears on 1,948 US grants and 2,906 published applications in this corpus.
Search patents in C07K- Granted patents
- 1,948
- Published applications
- 2,906
- Assignees
- 1,145
- Inventors
- 4,754
- Latest grant
- 1 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1989 | 2 | 0 |
| 1990 | 3 | 0 |
| 1991 | 2 | 0 |
| 1992 | 1 | 0 |
| 1993 | 16 | 0 |
| 1994 | 14 | 0 |
| 1995 | 17 | 0 |
| 1996 | 16 | 0 |
| 1997 | 34 | 0 |
| 1998 | 64 | 0 |
| 1999 | 66 | 0 |
| 2000 | 61 | 0 |
| 2001 | 54 | 6 |
| 2002 | 38 | 90 |
| 2003 | 37 | 140 |
| 2004 | 35 | 69 |
| 2005 | 38 | 74 |
| 2006 | 66 | 66 |
| 2007 | 35 | 61 |
| 2008 | 37 | 71 |
| 2009 | 49 | 98 |
| 2010 | 61 | 96 |
| 2011 | 52 | 75 |
| 2012 | 60 | 70 |
| 2013 | 51 | 100 |
| 2014 | 57 | 93 |
| 2015 | 53 | 102 |
| 2016 | 81 | 104 |
| 2017 | 76 | 140 |
| 2018 | 74 | 125 |
| 2019 | 92 | 133 |
| 2020 | 81 | 152 |
| 2021 | 96 | 197 |
| 2022 | 100 | 204 |
| 2023 | 76 | 171 |
| 2024 | 84 | 176 |
| 2025 | 105 | 179 |
| 2026 | 64 | 114 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Method for high level and stable gene transfer in lymphocytes1 Sep 2026US 12,723,265 B2Julius-Maximilians-UniversitäT WüRzburg
- Compounds with anti-tumor activity against cancer cells bearing HER2 exon 19 mutations25 Aug 2026US 12,714,708 B2Board of Regents, The University of Texas System
- TGF-beta RII mutant and fusion protein thereof25 Aug 2026US 12,715,904 B2Mabwell (Shanghai) Bioscience Co., Ltd.
- Methods of characterizing and purifying VEGF receptor fusion protein25 Aug 2026US 12,715,905 B2Regeneron Pharmaceuticals, Inc.
- Angiopoietin 2, VEGF dual antagonists25 Aug 2026US 12,715,912 B2AskGene Pharma Inc.
- Chimeric receptors8 Oct 2026US 2026/0306631 A1St. Jude Children?S Research Hospital
- Activin receptor type iib variants and uses thereof8 Oct 2026US 2026/0308229 A135PHARMA Inc.
- Recombinant fusion protein for treatment of pulmonary hypertension8 Oct 2026US 2026/0308230 A1
- Anti-vegf protein compositions and methods for producing the same8 Oct 2026US 2026/0308231 A1Regeneron Pharmaceuticals, Inc.
- Anti-vegf protein compositions and methods for producing the same8 Oct 2026US 2026/0308232 A1Regeneron Pharmaceuticals, Inc.
Most cited
By later US patents
- Expression and export technology of proteins as immunofusins276US 5,541,087 AFuji ImmunoPharmaceuticals Corporation · 1996
- Determination of status in neoplastic disease237US 4,968,603 AThe Regents of the University of California · 1990
- Human TRK receptors and neurotrophic factor inhibitors159US 5,844,092 AGenentech, Inc. · 1998
- Novel receptors for efficient determination of ligands and their antagonists or agonists158US 4,859,609 AGenentech, Inc. · 1989
- HER2 extracellular domain154US 6,015,567 AGenentech, Inc. · 2000